Clinical Trials Dictionary: Terminology and Usage Recommendations, Second Edition

Clinical Trials Dictionary: Terminology and Usage Recommendations, Second Edition

Volumn , Issue , 2012, Pages

  Meinert, Curtis L ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84891585384     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118315293     Document Type: Book

References (275)

1. Abraha I, Montedori A. Modified intention to treat reporting in randomised controlled trials: Systematic review. BMJ 2010;340:c2697; doi:10.1136/bmj.c2697. 129
2. Adapt Research Group. Cardiovascular and cerebrovascular results from the randomized, controlled Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 2006;1(7):e33. doi:10.1371/journal.pctr 52
3. Aickin M. A program for balancing the allocation of subjects to treatment in a clinical trial. Comput Biomed Res 1982;15:519-524. 157
4. The American Heritage Dictionary, 2nd College Edition. Houghton Mifflin Company, Boston, 1991. xvi, xxxviii, 10, 70
5. Anderson LK, Hendershot RA, Schoolmaker RC. Self-checking digit concepts. J Systems Manage 1974;25:36-42. 31
6. Angell M, Kassirer JP. The Ingelfinger rule revisited. N Engl J Med 1991;325:1,371-1,373. 127
7. Antman EM, Lau J, Kupeinick B, Mosteller F, Chalmers TC. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. JAMA 1992;268:240-248. 101
8. Armitage P. Attitudes in clinical trials. Stat Med 1998;17:2,675-2,683. 129
9. Armitage P, Colton T. Encyclopedia of Biostatistics (pages 4,898). John Wiley & Sons, Chichester, 1998. xvi
10. Armitage P, Berry G. Statistical Methods in Medical Research. Blackwell Scientific Publications, London, 1994. xvi
11. Armitage P. The analysis of data from clinical trials. The Statistician 1979;28:171-183. 129
12. Bartlett MS. The use of transformations. Biometrics 1947;3:39-52. 147
13. Bayan R. The Cynic's Dictionary. Hearst Books, New York, 1994. xxxviii
14. Bayes T. An essay towards solving a problem in the doctrine of chances. (Reproduced in Biometrika 1958;45:296-315.) Philos Trans R Soc Lond 1763;53:370-418. 18
15. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schultz KF, Simel D, Stroup DF. Improving the quality of reporting of randomized controlled trials: The CONSORT statement. JAMA 1996;276:637-639. 51, 303
16. Begg CB. Advances in statistical methodology for diagnostics medicine in the 1980's. Stat Med 1991;10:1,887-1,895. 226
17. Benford F. The law of anomalous numbers. Proc Am Philos Soc 1938;78:551-572. 19
18. Berkson J. Limitations of the application of fourfold table analysis to hospital data. Biometrics Bull 1946;2:47-53. 19
19. Bernoulli J: Ars Conjectandi. (Reprinted in Latin by Culture et Civilisation, 1968) Belgium, 1713. 19
20. Berry SM, Reese CS, Larkey PD. Bridging different eras in sports. J Am Stat Assn 1999;94:661-676. 168
21. Bierce A. The Devil's Dictionary. Dover Publications, Inc., New York, 1993. xvi
22. Black's Law Dictionary. West Publishing Company, St Paul, MN, 1990. xvi, 102
23. Bliss CI. The methods of probits. Science 1934;79:38-39. 209
24. Bliss CI. The method of probits-A correction. Science 1934;79:409-410. 209
25. Boissel J-P, Collet J-P, Moleur P, Haugh M. Surrogate endpoints: A basis for a rational approach. Eur J Clin Pharmacol 1992;43:235-244. 269
26. Bradley C. Designing medical and educational intervention studies: A review of some alternatives to conventional randomized controlled trials. Diabetes Care 1993;16:509-518. 203
27. Brain Resuscitation Clinical Trial II Study Group. A randomized clinical trial of calcium entry blocker administration to comatose survivors of cardiac arrest: Design, methods and patient characteristics. Control Clin Trials 1991;12:525-545. 68
28. Breslow NE, Day NE. Statistical Methods in Cancer Research, Vol 1. International Agency for Research on Cancer, Lyon, 1980. xvi
29. Brewin CR, Bradley C. Patient preferences and randomised clinical trials. BMJ 1989;299:313-315. 203
30. Brittain E, Wittes J. The run-in period in clinical trials. Control Clin Trials 1990;11:327-338. 142, 196
31. Brown CA, Lilford RJ: The stepped wedge trial design: A systematic review. BMC Medical Research Methodology 2005; doi:10.1186/1471-2288-6-54. 259
32. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston WA, Smink RD Jr, Sawin HS, Campos Ct, Hansen Bj, Tuna N, Karnegis Jn, Sanmarco Me, Amplatz K, Castaneda-Zuniga Wr, Hunter Dw, Bissett Jk, Weber Fj, Stevenson Jw, Leon As, Chalmers Tc, And The Posch Group. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990;323:946-955. 76
33. Buyse ME, Staquet MJ, Sylvester Rj (Eds.). Cancer Clinical Trials: Methods and Practice. Oxford University Press, Oxford, 1984. xvi
34. Byar DP, Schoenfeld DA, Green SB, Amato DA, Davis R, De Gruttola V, Finkelstein DM, Gastonis C, Gelber RD, Lagakos S, Lefkopoulou M, Tsiatis AA, Zelen M, Peto J, Freedman LS, Gail M, Simon R, Ellenberg SS, Anderson JR, Collins R, Peto R, Peto T. Design considerations for AIDS trials. N Engl J Med 1990;323:1,343-1,348. 292
35. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W, For The Coronary Drug Project Research Group. Fifteen year mortality in Coronary Drug Project patients: Longterm benefit with niacin. J Am Coll Cardiol 1986;8:1,245-1,255. 100
36. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-412. 142
37. Carter SK. Clinical trials in cancer chemotherapy. Cancer 1977;40:544-557. 154
38. CASS PRINCIPAL INVESTIGATORS AND THEIR ASSOCIATES. Coronary Artery Surgery Study (CASS): A randomized trial of coronary artery bypass surgery: Comparability of entry characteristics and survival in randomized patients and nonrandomized patients meeting randomization criteria. J Am Coll Cardiol 1984;3:114-128. 262
39. CASS PRINCIPAL INVESTIGATORS AND THEIR ASSOCIATES. National Heart, Lung, and Blood Institute Coronary Artery Surgery Study (CASS): A multicenter comparison of the effects of randomized medical and surgical treatment of mildly symptomatic patients with coronary artery disease, and a registry of consecutive patients undergoing coronary angiography. Circulation 1981;63 (monograph 79) (Part II):I-1-I-81. 262
40. Chan A, Altman DG: Identifying outcome reporting bias in randomised trials on PubMed: Review of publications and survey of authors. BMJ 2005; doi:10.1136/bmj.38356.424606.8F. 182
41. Chandor A. The Facts on File Dictionary of Microcomputers. Facts on File, Inc., New York, 1981. xvi
42. Chow S-C, Chang M: Adaptive design methods in clinical trials - A review. Orphanet J Rare Dis 2008 3:11; doi: 10.1186/1750-1172-3-11 PMCID: PMC2422839. 2
43. Cochran WG, Cox GM. Experimental Designs (2nd ed.). John Wiley & Sons, Inc, New York, 1957. xvi
44. Cochrane AL: Effectiveness and Efficiency: Random Reflections on Health Services. The Nuffield Provincial Hospitals Trust, London, 1972. 80
45. Coordinating Center Models Project Research Group: Coordinating Center Models Project: A Study of Coordinating Centers in Multicenter Clinical Trials: I. Design and Methods (in two parts). Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute, Bethesda, MD, 1979. xi
46. Coordinating Center Models Project Research Group: Coordinating Center Models Project: A Study of Coordinating Centers in Multicenter Clinical Trials: IV. Terminology. Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute, Bethesda, MD, 1979. xi
47. Cornfield J. The Bayesian outlook and its application (including discussion by S Geisser, HO Hartley, O Kempthrone, H Rubin). Biometrics 1969;25:617-657. 18
48. Cornfield J. Sequential trials, sequential analysis and the likelihood principle. Am Stat 1966;20:18-23. 18, 144, 231
49. Coronary Drug Project Research Group. The Coronary Drug Project: Design, Methods, and Baseline Results. Circulation 1973;47(suppl. 1):I-1-I- 50. 21, 43, 142, 162, 185, 196, 245, 252, 256
50. Cox DR. Regression models and life tables (including discussion). JRSS 1972;34(series B):187-220. 59
51. Cronbach LJ. Coefficient alpha and the internal structure of tests. Phychometrika 1951;16:297-333. 59
52. David FN. A power function for tests of randomness in a sequence of alternatives. Biometrika 1947;34:335-339. 289
53. David HA. First (?) occurrence of common terms in mathematical statistics. Am Statistician 1995;49:121-133. xvi
54. Day S. Dictionary for Clinical Trials (217 pgs). John Wiley & Sons, Ltd., Chichester, 1999. xvi
55. Demets DL, Lan Kkg. Interim analysis: The alpha spending function approach. Stat Med 1994;13:1,341-1,352. 7, 111
56. Demets DL, Ware JH. Group sequential methods for clinical trials with a one-sided hypothesis. Biometrika 1980;67:651-660. 111
57. DEPARTMENT OF HEALTH AND HUMAN SERVICES. Public Health Services policies on research misconduct; 42 CFR Parts 50 and 93. Federal Register 2005;70:28,370-28,400. 236
58. Department of Health and Human Services; Office for Civil Rights: Standards for privacy of individually identifiable health information (Unofficial version) (45 CFR Parts 160 and 164): Regulation text (28 Dec 2000: as amended: Part 160 (31 May 2002); Parts 160, 164 (14 Aug 2002); 31 pages; Oct 2002. 69, 114, 145
59. DEPARTMENT OF HEALTH AND HUMAN SERVICES; FOOD AND DRUG ADMINISTRATION. Electronic records; electronic signatures. Federal Register 1997;62:13,429-13,466. 82
60. DEPARTMENT OF HEALTH AND HUMAN SERVICES. Protection of human subjects; informed consent and wavier of informed consent requirements in certain emergency research; final rules. Federal Register 1996;61:51,498-51,533. 41
61. DEPARTMENT OF HEALTH AND HUMAN SERVICES. Expanded availability of investigational new drugs through a parallel track mechanism for people with AIDS and other HIV-related disease. Federal Register 1992;57:13,250-13,259. 186
62. Diaconis P, Efron B. Computer-intensive methods in statistics. Sci Am 1983;248:116-130. 25, 137
63. Dickersin K, Berlin JA. Meta-analysis: Stateof- the science. Epidemiol Rev 1992;14:154-176. 105
64. Diggle P, Kenward MG. Informative dropout in longitudinal data analysis. Appl Statist 1994;43:49-93. 126
65. Dixon WJ, Mood AM. A method for obtaining and analyzing sensitivity data. JASA 1948;43:109-126. 296
66. Dorland's Illustrated Medical Dictionary (24th ed.). WB Saunders Co., Philadelphia, 1965. xvi
67. Dubois D, Dubois EF. A formula to estimate the approximate surface area if height and weight are known. Arch Intern Med 1916;17:863-871. 169
68. Dupont WD: Sequential stopping rules and sequentially adjusted p-values; Does one require the other? Control Clin Trials 1983;4:3-10. 144
69. Eberly LE, Neaton JD, Thomas AJ, Dai Y For The Multiple Risk Factor Intervention Trial Research Group. Multiple-stage screening and mortality in the Multiple Risk Factor Intervention Trial. Clin Trials 2004;1:148-161. 100
70. Edwards Awf: Likelihood: An account of the Statistical Likelihood Concept of Likelihood and its Application to Scientific Inference. Cambridge University Press, Cambridge, 1972. 144
71. Efron B. Forcing a sequential experiment to be balanced. Biometrika 1971;58:403-417. 1
72. Federer WT. Experimental Design, Theory and Application. Oxford and India Book House, Calcutta, 1967. xvi
73. Fellegi IP, Sunter A. A theory for record linkage. JASA 1969;64:1,183-1,210. 31
74. Feller W: An Introduction to Probability Theory and Its Applications (Vol. 1, 3rd ed.). JohnWiley & Sons, New York, 1968. xvi, 19, 25
75. Fergusson D, Glass KC, Hutton B, Shapiro S: Randomized controlled trials of aprotinin in cardiac surgery: Could clinical equipoise have stopped the bleeding? Clin Trials 2005;2:218-232. 32, 60
76. Finney DJ. On biometrics language and its abuses. Biometrics Bull 1994;11:2-4. 224
77. Fisher RA: The Design of Experiments. Oliver & Boyd, Edinburgh, 1935. 93
78. Fleming TR, Harrington DP, O'brien PC. Designs for group sequential tests. Control Clin Trials 1984;5:348-361. 111
79. Food and Drug Administration: Code of Federal Regulations; 21, Parts 800-1299, Revised as of April 1, 1999. Office of the Federal Register, National Archives and Records Administration, Washington, DC, 1999. 117, 155
80. Food and Drug Administration: Guidance for Industry: E6 Good Clinical Practice: Consolidated Guidance, 58 pages, April 1996 (http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073122.pdf). 109
81. Food and Drug Administration: Code of Federal Regulations; 21, Revised as of April 1, 1994 (all parts) 9 volumes: Parts 1-99, 100-169, 170-199, 200-299, 300-499 (drugs), 500-599, 600-799 (biologics and blood products), 800-1299 (devices), and 1300-end; Chapter I: Food and Drug Administration, Department of Health and Human Services, Parts 1-1299; Chapter II: Drug Enforcement Administration, Department of Justice, Parts 1300-1316; Chapter III: Office of National Drug Policy Control Policy, Parts 1400-1499. Office of the Federal Register, National Archives and Records Administration, Washington, DC, 1994. 194
82. Food and Drug Administration: Code of Federal Regulations; 21, Parts 300-499, Revised as of April 1, 1994. Office of the Federal Register, National Archives and Records Administration, Washington, DC, 1994. 4, 134, 249, 293
83. Food and Drug Administration. International conference on harmonisation; draft document on good clinical practices; guidelines for the investigator's brochure. Federal Register 1994;59:40,772-40,787. 114
84. Food and Drug Administration: FDA Regulatory Manual Series, Vol. 1, James T O'Reilly. McGraw-Hill, New York, 1984. 108
85. Food and Drug Administration: National Center for Devices and Radiological Health: Regulatory Requirements for Medical Devices:A Workshop Manual, Publ. no. FDA 83-4,165. Rockville, MD, 1983. 133, 154, 204
86. Food and Drug Administration: Guidance for industry: Good laboratory practices questions and answers. (25 pages) June 1981. 109
87. Food and Drug Administration: General Considerations for the Clinical Evaluation of Drugs. Publ. no. HEW (FDA) 77-3040, Rockville, MD, 1977. 193, 194
88. Food And Drug Administration. Applicability of Drug Efficacy Study Implementation notices and notices of opportunity for hearing to identical, related, and similar drug products. Federal Register 29 March 1974;39:11,681-11,682. 77, 108
89. Fost N, Robertson JA. Deferring consent with incompetent patients in an intensive care unit. IRB: Rev Hum Sub Res 1980;2(7):5-6. 68
90. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med 1987;317:141-145. 34
91. Frangakis CE, Rubin DB. Principal stratification in causal inference. Biometrics 2002;58:21-29. 208
92. Freidlin B, Korn EL, Gray R. A general inefficacy interim monitoring rule for randomized clinical trials. Clin Trials 2010;7:197-208. 126
93. Freiman JA, Chalmers TC, Smith H, Kuebler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial: Survey of 71 "negative" trials". N Engl J Med 1978;290:690-694. 101
94. Freund FE, Williams FJ. Dictionary/Outline of Basic Statistics. McGraw-Hill Book Company, New York, 1966. xvi
95. Friedman B. A simple urn model. Comm Pure and Appl Math 1949;2:59-70. 296
96. Friedman LM, Furberg CD, Demets DL. Fundamentals of Clinical Trials (2nd ed.). PSG Publishing Co., Inc., Boston, Massachusetts, 1985. xvi
97. Galton F. Regression towards mediocrity in hereditary stature. Anthro Inst 1886;15:246-263. 229, 230
98. Gifis SH: Law Dictionary. Barron's Educational Series, Inc., Woodbury, NY, 1984. xvi, 122
99. Gill JL. Design and Analysis of Experiments in the Animal and Medical Sciences (vol. 2). Iowa State University Press, Ames, IA, 1978. xvi
100. Glass GV. Primary, secondary and metaanalysis of research. Educ Res 1976;5:3-8. 156
101. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 3. Design and methods. Control Clin Trials 1991;12:504-524. 186
102. Gompertz B. On the nature of the function expressive of the law of human mortality. Phil Trans R Soc (A) 1825;115:513-583. 108
103. Gordis L: Epidemiology. WB Saunders Co., Philadelphia, 1996. 12
104. Grizzle JE. The two-period change-over design and its use in clinical trials. Biometrics 1965;21:467-480. 289
105. Guyatt G, Sackett D, Taylor DW, Chong J, Roberts R, Pugsley S. Determining optimal therapy-Randomized trials in individual patients. N Engl J Med 1986;314:889-892. 165
106. Hanley JA. Receiver operating characteristic (ROC) methodology: The state of the art. Crit Rev Diagn Imaging 1989;29:307-335. 226
107. Haybittle JL. Repeated assessment of results in clinical trials of cancer treatment. J Radiol 1971;44:793-797. 111
108. Henneken CH, Eberlein K, For The Physicians' Health Study Research Group. A randomized trial of aspirin and β-carotene among U.S. physicians. Prev Med 1985;14:165-168. 21, 252
109. Hill AB: Principles of Medical Statistics (7th ed.). Oxford University Press, New York, 1961. 129
110. Hill TP. The first digit phenomenon. Am Sci 1998;86:358-363. 19
111. Hoaglin DC, Mosteller F, Tukey JW: Understanding Robust and Exploratory Data Analysis. John Wiley & Sons, New York, 1983. xvi, 302
112. Huber PJ: Robust statistics. John Wiley & Sons, New York, 1981. 302
113. Hutchinson DR. Dictionary of Clinical Research (2nd ed.). Brookwood Medical Publications, Richmond, Surrey, UK, 1998. xvi
114. Ingelfinger Fj (Editor). Definition of "sole" contribution. N Engl J Med 1969;281:676-677. 127
115. Institute of Medicine Committee on Comparative Effectiveness Research Prioritization: Initial National Priorities for Comparative Effectiveness Research (252 pages). National Academies Press, Washington, DC, 2009. 41
116. Institute of Medicine, Committee to Review the Fialuridine (FIAU/FIAC) Clinical Trials: Review of the Fialuridine (FIAU) Clinical Trials. National Academies Press, Washington, DC, 1995. 233
117. INTERNATIONAL COMMITTEE OF MEDICAL JOURNAL EDITORS. Uniform requirements for manuscripts submitted to biomedical journals. N Engl J Med 1997;336:309-315. 12, 294, 299
118. Jama Editorial. The new federal food and drug act at last. JAMA 1938;111:324-326. 77
119. James G, James Rc (Eds.). Mathematics Dictionary (4th ed.). Van Nostrand Reinhold Company, New York, 1976. xvi
120. Jelliffe DB, Jelliffe Efp. Underappreciated pioneers. Am J Clin Nutr 1979;32:2,519-2,521. 219
121. Johnson S: A Dictionary of the English Language. (in two vols.). Printed by W Strahan, for J and P Knapton; T and T Longman; C Hitch and L Hawes; A Millar; and R and J Dodsley, 1755. vi, xi
122. Jones JH: Bad Blood. The Tuskegee Syphilis Experiment. The Free Press, New York, 1981. 89
123. Kahn HA, Sempos CT: Statistical Methods in Epidemiology. Oxford University Press, New York, 1989. 72, 177
124. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. JASA 1958;53:457-481. 138
125. Katz J: Experimentation with Human Beings. Russell Sage Foundation, New York, 1972. 113
126. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged-The index of ADL: A standardized measure of biological and psychosocial function. JAMA 1963;185:914-919. 2
127. Kempthorne O. The Design and Analysis of Experiments. John Wiley & Sons, New York, 1952. xvi
128. Kendall MG, Buckland WR. A Dictionary of Statistical Terms (2nd ed.). Hafner Publishing Company, New York, 1960. xvi
129. Kendall MG. A new measure of rank correlation. Biometrika 1938;30:81-93. 139
130. Kennedy D. A calm look at the "drug lag". JAMA 1978;239:423-426. 77
131. Kenward MG, Jones B. The analysis of data from 2×2 cross-over trials with baseline measurements. Stat Med 1987;6:911-926. 289
132. Kirk RE. Experimental Design: Procedures for Behavioral Sciences. Brooks/Cole, Monterey, CA, 1982. xvi
133. Kish L: Survey Sampling. John Wiley & Sons, New York, 1965. 70
134. Klein E. A Comprehensive Etymological Dictionary of the English Language. Elsevier Scientific Publishing Co., Amsterdam, 1971. xvi
135. Klumpp TG. The new federal food, drug, and cosmetic Act. JAMA 1939;113:2,233-2,235. 77
136. Knuth DE: Seminumerical Algorithms (Vol. 2; Art of Computer Programming). Addison-Wesley Publishing Co., Reading, MA, 1969. 213
137. Kotz S, Johnson NL, Read Bc (Eds.). Encyclopedia of Statistical Sciences. John Wiley & Sons, New York, 1982. xvi
138. Kruskal WH, Tanur Jm (Eds.). International Encyclopedia of Statistics (in 2 vols). The Free Press, Macmillan Publishing Co., Inc., New York, 1978. xvi
139. Laine C, Horton R, Deangelis CD, Drazen JM, Frizelle FA, Godlee F, Haug C, Hébert PC, Kotzin S, Marusic A, Sahmi P, Schroeder TV, Sox HC, Van Der Weyden MB, Verheugt Fwa. Clinical trial registration: Looking back and moving ahead. Ann Intern Med 2007;147:275-277. 35
140. Lan Kkg, Demets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-663. 111
141. Last JM (ed.): A Dictionary of Epidemiology (4th ed.). Oxford University Press, New York, 2001. xvi, 48
142. Last JM. Making the dictionary of epidemiology. Int J Epidemiol 1996;25:1,098-1,101. 85
143. Last JM (ed.): A Dictionary of Epidemiology (3rd ed.). Oxford University Press, New York, 1995. xvi, 12, 80, 81, 84, 85
144. Last JM (ed.): A Dictionary of Epidemiology (2nd ed.). Oxford University Press, New York, 1988. xvi, 28, 79, 115, 177, 207, 245, 274
145. Last JM (ed): A Dictionary of Epidemiology. Oxford University Press, New York, 1983. xvi, 48
146. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988;318:1,728-1,733. 173
147. Lenter M, Bishop T. Experimental Design and Analysis. Valley, Blacksburg, VA, 1986. xvi
148. Leventhal BG, Wittes RE. Research Methods in Clinical Oncology. Raven Press, New York, 1988. xvi
149. Levine RJ. Deferred consent. Control Clin Trials 1991;12:546-550. 68
150. Levine RJ: Ethics and Regulation of Clinical Research (2nd ed.). Yale University Press, New Haven, CT, 1988. xvi, 19, 42, 128, 138, 173, 237, 303
151. Lewis S, Clarke M. Forest plots: Trying to see the wood and the trees. BMJ 2001;322:1,479-1,480. 101
152. Liang K, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22. 108
153. Likert R. A technique for measurement of attitudes. Arch Psychol 1932;140:5-55. 145
154. Lilienfeld AM, Lilienfeld DE. Foundations of Epidemiology (2nd ed.). Oxford University Press, New York, 1980. xvi
155. Lind J. A Treatise of the Scurvy (reprinted in Lind's Treatise on Scurvy, edited by CP Stewart, D Guthrie, Edinburgh University Press, Edinburgh, 1953). Sands, Murray, Cochran, Edinburgh, 1753. xi
156. Lumley T. Network meta-analysis for indirect treatment comparisons. Statist Med 2002;21:2,313-2,324. 168
157. Macmahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease: Part 1. Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-774. 229
158. Macular Photocoagulation Study Group. Argon laser photocoagulation for ocular histoplasmosis: Results of a randomized clinical trial. Arch Ophthalmol 1983;101:1,347-1,357. 161
159. Macular Photocoagulation Study Group. Argon laser photocoagulation for senile macular degeneration: Results of a randomized clinical trial. Arch Ophthalmol 1982;100:912-918. 161
160. Mann HB, Whitney DR. On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat 1947;18:50-60. 151
161. Manson JM: Testing of Pharmaceutical Agents for Reproductive Toxicity. In Developmental Toxicology (2nd ed.), CA Kimmel and J Buelke-Sam, eds., Raven Press, New York, 1994. 78
162. Mantel N. Synthetic retrospective studies and related topics. Biometrics 1973;29:479-486. 28
163. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-170. 148
164. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-748. 151
165. Marriott Fhc. A Dictionary of Statistical Terms (5th ed.). Longham Scientific and Technical, Essex, England, 1990. xvi
166. Martin BM, Meinert CL, Breitner Jcs For The Adapt Research Group. Double placebo design in a prevention trial for Alzheimer's disease. Controlled Clin Trials 2002;23:93-99. 154, 162
167. Meadows AJ. Dictionary of New Information Technology. Nichols Publishing Co., New York, 1982. xvi
168. Meinert CL. Redesign of trials under different enrollment mixes. Statist Med 1999;18:241-251. 163
169. Meinert CL. Beyond CONSORT: Need for improved reporting standards for clinical trials. JAMA 1998;279:1,487-1,489. 51
170. Meinert CL. Clinical Trials Dictionary: Terminology and Usage Recommendations. The Johns Hopkins Center for Clinical, Baltimore, 1996. xvi
171. Meinert CL. An open letter to the FDA regarding changes in reporting procedures for drugs and biologics proposed in the wake of the FIAU tragedy. Control Clin Trials 1996;17:273-284. 232
172. Meinert CL, Tonascia S: Clinical Trials: Design, Conduct, and Analysis. Oxford University Press, New York, 1986. xvi, xi, 8, 42, 58, 72
173. Meinert CL. Terminology-A plea for standardization (editorial). Control Clin Trials 1980;1:97-99. xi
174. Metz CE: Basic principles of ROC analysis. Semin Nucl Med 1978; VIII:283-298. 226
175. Michael M, Boyce WT, Wilcox AJ: Biomedical Bestiary: An Epidemiologic Guide to Flaws and Fallacies in the Medical Literature. Little, Brown and Company, Boston, 1984. 79
176. Miller RG. The jackknife-A review. Biometrika 1974;61:1-15. 137
177. Miller-Keane Encyclopedia & Dictionary of Medicine, Nursing, & Allied Health (5th ed.). WB Saunders Co., Philadelphia, 1992. xvi
178. Moher D. CONSORT: An evolving tool to help improve the quality of reports of randomized controlled trials. JAMA 1998;279:1,489-1,491. 51
179. Montgomery DC. Design and Analysis of Experiments (2nd ed.). John Wiley & Sons, New York, 1984. xvi
180. Morganstern H, Bursic ES. A method for using epidemiologic data to estimate the potential impact of an intervention on the health status of a target population. J Community Health 1982;7:292-309. 239
181. Morris W (Ed.). The American Heritage Dictionary of the English Language. American Heritage PublishingCo., andHoughtonMifflin Co., NewYork, 1973. xvi
182. Mosteller F. A k-sample slippage test for an extreme population. Ann Math Stat 1948;19:58-65. 289
183. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial. Risk factor changes and mortality results. JAMA 1982;248:1,465-1,477. 163, 239
184. Murray Jah, Bradley H, Craigie WA, Onion CT (eds.): The Oxford English Dictionary: A New English Dictionary on Historical Principles (in 13 volumes). Clarendon Press, Oxford, 1970. xvi, 102
185. Murray Kme: Caught in the Web of Words: James Murray and the Oxford English Dictionary. Oxford University Press, Oxford, 1979. xi, xv
186. National Center for Health Statistics: Vital Statistics of the United States, 1989; Vol II: Mortality, Part A. U.S. Government Printing Office. Pub. no. (PHS) 93-1101, Washington, DC, 1993. 144
187. National Center for Health Statistics: Health, United States, 1992. DHHS pub. no. (PHS) 93-1232, Hyattsville, MD, 1993. 46, 144
188. National Center for Health Statistics: National Death Index: User's Manual. Publ. no. (PHS) 81-1148, Hyattsville, MD, Sept, 1981. 165
189. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research: The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research.U.S. Government Printing Office; 1983-381- 132:3205, Washington, DC, 1979. 18, 138
190. National Institutes Of Health. Directory sources: The federal health tree. J NIH Res 1994;6:67-69. 101
191. National Institutes Of Health. NIH Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Rese. (Also in NIH Guide Grants Contracts 23: 2-10, 18 March 1994) Federal Register March 28, 1994;59:14,508-14,513. 194, 297
192. National Institutes of Health: Clinical trials activity (NIH Clinical Trials Committee; Rs Gordon JR, Chair). NIH Guide Grants Contracts 5 June 1979. 8): 29. 9, 42
193. National Library of Medicine: Medical subject headings - Annotated alphabetic list: 1998. National Library of Medicine, Bethesda, Maryland, 1997. 34, 55
194. National Research Council, Division of Medical Sciences: Drug Efficacy Study: Final Report to the Commissioner of Food and Drug Administration. National Academy of Sciences, Washington, DC, 1969. 77, 108
195. Nelder JA, Wedderburn Rwm. Generalised linear models. JRSS(A) 1972;135:370-384. 108
196. Newcomb S. Note on the frequency of the use of digits in natural numbers. Am J Math 1881;4:39-40. 19
197. Nutton V: What's in an oath? J R Coll Physicians Lond 1995;29:518-524. 113
198. O'brien PC: Data and safety monitoring. Encyclopedia of Biostatistics, Vol. 2, John Wiley & Sons, Chichester, 1,058-1,066, 1998. 260
199. O'brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-556. 111
200. Office for Protection from Research Risks: Code of Federal Regulations, Title 45: Public Welfare, Part 46: Protection of Human Subjects. Department of Health and Human Services, National Institutes of Health, Bethesda, MD (revised) 18 June 1991. 7, 40, 48, 49, 51, 72, 87, 88, 117, 128, 135, 156, 178, 235, 236
201. O'quigley J, Pepe M, Fisher L. Continual reassessment method: A practical design for phase 1 clinical trials in cancer. Biometrics 1990;46:33-48. 53
202. Packard FR: Life and Times of Ambroise Paré, 1510-1590. Paul B Hoeber, New York, 1921. 35, 89
203. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, Mcpherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 1977;35:1-39. 111, 183
204. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, Mcpherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: I. Introduction and design. Br J Cancer 1976;34:585-612. 111
205. Peto R, Peto J. Asymptotically efficient rank invariant test procedures (with discussion). J R Stat Soc A 1972;135:185-206. 148
206. Physicians' Desk Reference (52nd ed.). Medical Economics Data Production Co., Montvale, NJ, 1998. 141, 195
207. Physicians' Health Study Research Group Steering Committee. Preliminary report: Findings from the aspirin component of the ongoing Physicians' Health Study. NEngl J Med 1988;318:262-264. 163, 252
208. Piantadosi S: Clinical Trials: A Methodologic Perspective (2nd ed.; 687 pages). John Wiley & Sons, Hoboken, NJ, 2005. 195
209. Pines WL: A Primer on New Drug Development. Publ. no. 1980-311-254/83, Food and Drug Administration, Rockville, MD, 1980. 193, 194
210. Pocock SJ: Clinical Trials: A Practical Approach. John Wiley & Sons, Chichester, 1983. xvi, 129, 157
211. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika 1977;64:191-199. 111
212. Prentice RL. Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med 1989;8:431-440. 269
213. Prentice RL. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 1986;73:1-11. 28
214. Quetelet A: Sur l'Homme et el Dévloppement des Facultés. Hauman, Brussels, 1836. 219
215. Rennie D. How to report randomized controlled trials: The CONSORT statement. JAMA 1996;276:649. 51
216. Rennie D. Reporting randomized trials: An experiment and a call for responses from readers. JAMA 1995;273:1,054-1,055. 51
217. Robbins H. A sequential decision problem with finite memory. Proc Natl Acad Sci USA 1956;42:920-923. 199, 289
218. Robbins H. Some aspects of the sequential design of experiments. Bull Am Math Soc 1952;58:527-535. 199, 289
219. Robin ED, Mccauley RF. Cultural lag and the Hippocratic Oath. Lancet 1995;345:1,422-1,424. 113
220. Roethlisberger FJ, Dickson WJ: Management and the Worker. John Wiley & Sons, New York, 1964. 114
221. Rothman KJ (ed.): Causal Inference. Epidemiology Resources Inc., Chestnut Hill, MA, 1988. 28
222. Royall RM. Ethics and statistics in randomized clinical trials. Stat Sci 1991;6:52-88. 42
223. Rücker G. A two-stage trial design for testing treatment, self-selection and treatment preference effects. Stat Med 1989;8:477-485. 203
224. Sackett DL. The competing objectives of clinical trials. N Engl J Med 1980;303:1,059-1,060. 90, 151, 202
225. Sackett DL, Gent M. Controversy in counting and attributing events in clinical trials. N Engl J Med 1979;301:1,410-1,412. 90, 129, 151, 202
226. Savage IR. Contributions to the theory of rank order statistics-The two sample case. Ann Math Stat 1956;27:590-615. 148
227. Schlesselman JJ. Case-Control Studies: Design, Conduct, and Analysis. Oxford University Press, New York, 1982. xvi
228. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutic trials. J Chronic Dis 1967;20:637-648. 90, 129, 151, 202, 203
229. Selmer ES. Registration numbers in Norway: Some applied number theory and psychology. JRSS 1967;130(series A): 225-231. 31
230. Senn S. Suspended judgement n-of-1 trials. Control Clin Trials 1993;14:1-5. 165
231. Shimm DS, Spece RG. Ethical issues and clinical trials. Drugs 1993;46:579-584. 34
232. Shuster E. Fifty years later: The significance of the Nuremberg Code. N Engl J Med 1997;337:1,436-1,440. 173
233. Simon R. Adaptive treatment assignment method and clinical trials. Biometrics 1977;33:743-749. 2
234. Sippl CJ: Computer Dictionary (4th ed.). Howard W Sams & Co., Indianapolis, 1985. xvi
235. Smith CV, Pyke R. The Robbins-Isbell twoarmed- bandit problem with finite memory. Ann Math Stat 1965;36:1,375-1,386. 289
236. Smythe M: Record numbering (In Record Linkage in Medicine. HD Achison, ed.), pages 179-187, Williams & Wilkins, Baltimore, 1968. 31
237. Snedecor GW, Cochran WG: Statistical Methods (6th ed.). The Iowa State University Press, Ames, IA, 1967. 256
238. Soukhanov Ah (Ed.). Webster's II New Riverside University Dictionary. The Riverside Publishing Co., Houghton Mifflin Co., Boston, 1988. xvi
239. Standards Of Reporting Trials Group. A proposal for structured reporting of randomized controlled trials. JAMA 1994;272:1,926-1,931. (correction JAMA 1995;273:776.) 51
240. Stedman, TL: Stedman's Medical Dictionary (25th ed). Williams & Wilkins, Baltimore, 1982. xvi
241. Stokes J, Noren J, Shindell S. Definition of terms and concepts applicable to clinical preventive medicine. J Community Health 1982;8:33-41. xvi
242. Strunk RC, Sternberg AL, Szefler SJ, Zeiger RS, Bender B, Tonascia J, On Behalf Of The Childhood Asthma Management Program (Camp) Research Group. Long-term budesonide or nedocromil treatment, once discontinued, does not alter the course of mild to moderate asthma in children and adolescents. J Pediatr 2009;154:682-687. 100
243. Studies Of Ocular Complications Of Aids Research Group, In Collaboration With The Aids Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992;326:213-220. 190, 268, 291
244. Taves DR. Minimization: A new method of assigning patients to treatment and control groups. Clin Pharmacol Ther 1974;15:443-453. 157
245. Taylor SH, Silke B, Ebbutt A, Sutton GC, Prout BJ, Burley DM. A long-term prevention study with oxprenolol in coronary heart disease. N Eng J Med 1982;307:1,293-1,301. 245
246. Teratology Society Public Affairs Committee. FDA classification of drugs for teratogenic risk. Teratology 1994;49:446-447. 78
247. Thomas CL (ed.): Taber's Cyclopedic Medical Dictionary (15th ed.). FADavisCo, Philadelphia, 1985. xvi
248. Thorburn WM: The myth of Occam's razor. Mind 1918; (new series) 27:345-353. 176
249. Tukey JW: Exploratory Data Analysis. Addison-Wesley Publishing Co., Reading, MA, 1977. 26
250. United States Congress (105th; 1st session): Food and Drug Administration Modernization Act of 1997 (21 USC § 301 et seq.). 1997. 143
251. United States Congress (103rd; 1st session): NIH Revitalization Act of 1993, 42 USC § 131 (1993); Clinical Research Equity Regarding Women and Minorities; Part I: Women and Minorities as Subjects in Clinical Research. 1993. xxxix, 166, 178, 297
252. University Group Diabetes Program Research Group. The effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: I. Design, methods and baseline characteristics. Diabetes 1970;19 (suppl. 2): 747-783. 163, 196, 210
253. University Group Diabetes Program Research Group. The effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: II. Mortality results. Diabetes 1970;19(suppl. 2): 785-830. 39
254. Vozeh S. The International Conference on Harmonisation. Eur J Clin Pharmacol 1995;48:173-175. 114
255. Warner S. Randomized response: A survey technique for eliminating evasive answer bias. JASA 1965;10:63-69. 224
256. Watson D: A Dictionary of Mind and Body. André Deutsch Limited, London, 1995. xvi
257. Webster's Eleventh New Collegiate Dictionary. Merriam-Webster Inc., Springfield, MA, 2009. xvi
258. Webster's Tenth New Collegiate Dictionary. Merriam-Webster Inc., Springfield, Mass, 1998. xvi
259. Webster's Ninth New Collegiate Dictionary. Merriam-Webster Inc., Springfield, Mass, 1991. xvi, xxxiii
260. Wei LJ, Lachin JM. Properties of the urn randomization in clinical trials. Control Clin Trials 1988;9:345-364. 296
261. Wei LJ. A class of designs for sequential clinical trials. JASA 1977;72:382-386. 296
262. Weik MH. Standard Dictionary of Computers and Information Processing. Hayden Book Company, Inc., New York, 1970. xvi
263. Wetherill GB. Sequential estimation of quantal response curves. J R Stat Soc 1963;25 (series B): 1-48. 296
264. Whitmore GA, Yalovsky M. A normalizing logarithmic transformation for inverse Gaussian random variables. Technometrics 1978;20:207-208. 147
265. Wilcoxon F. Individual comparisons by ranking methods. Biometrics Bull 1945;1:80-83. 151, 302
266. Winau R. The hippocratic oath and ethics in medicine. Forensic Sci Int 1994;69:285-289. 113
267. Wittes J, Lakatos E. Surrogate endpoints in clinical trials: Cardiovascular diseases. Stat Medicine 1989;8:415-425. 269
268. Working Group On Recommendations For Reporting Of Clinical Trials In The Biomedical Literature. Call for comments on a proposal to improve reporting of clinical trials in the biomedical literature: A position paper. Ann Intern Med 1994;121:894-895. 51
269. Wright S. The method of path coefficients. Ann Math Stat 1934;5:161-215. 188
270. Wright S. On the nature of size factors. Genetics 1918;3:367-374. 188
271. Yates F. Contingency tables involving small number and the χ2 test. J R Stat Soc 1934;1(suppl.):217-235. 305
272. Yusuf S, Simon R, Ellenberg S (Eds.). Proceedings of the workshop on methodologic issues in overviews of randomized clinical trials, May 1986. Stat Med 1987;6:217-410. 183
273. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: An overview of the randomized trial. Prog Cariovasc Dis 1985;27:335-371. 183
274. Zelen M. A new design for randomized clinical trials. N Engl J Med 1979;300:1,242-1,245. 201
275. Zelen M. Play the winner rule and the controlled clinical trial. JASA 1969;64:131-146. 199, 289